Literature DB >> 28272967

The basics of CAR T design and challenges in immunotherapy of solid tumors - Ovarian cancer as a model.

Xuequn Xu1, Jin Qiu1, Yi Sun1.   

Abstract

Chimeric antigen receptor T cells are T cells genetically engineered with CAR constructs which mainly contain scFV and TCR zeta chain. With promising development in blood cancers, CAR T trials are also applied in solid cancers. However, the treatment effect in solid cancers is lower than expected. This review summarizes difference of CAR T applications in solid and blood cancers. Future challenges of CAR T cell treatment in solid cancer are also discussed using ovarian cancer as an example.

Entities:  

Keywords:  FAS/FASL; activation induced cell death (AICD); blood cancer; chimeric antigen receptor T cells (CAR T); clinical trial; mesothelin; ovarian cancer; solid cancer

Mesh：

Substances：

Year:  2017        PMID： 28272967      PMCID： PMC5512759          DOI： 10.1080/21645515.2017.1291473

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  54 in total

1.  Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.

Authors:  Andreas A Hombach; Hinrich Abken
Journal:  Immunotherapy       Date:  2013-07       Impact factor: 4.196

2.  Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia.

Authors:  David M Barrett; Xiaojun Liu; Shuguang Jiang; Carl H June; Stephan A Grupp; Yangbing Zhao
Journal:  Hum Gene Ther       Date:  2013-08       Impact factor: 5.695

3.  Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

Authors:  Gianpietro Dotti; Barbara Savoldo; Martin Pule; Karin C Straathof; Ettore Biagi; Eric Yvon; Stephane Vigouroux; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

4.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

5.  Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.

Authors:  Sebastian Kobold; Julius Steffen; Michael Chaloupka; Simon Grassmann; Jonas Henkel; Raffaella Castoldi; Yi Zeng; Markus Chmielewski; Jan C Schmollinger; Max Schnurr; Simon Rothenfußer; Dolores J Schendel; Hinrich Abken; Claudio Sustmann; Gerhard Niederfellner; Christian Klein; Carole Bourquin; Stefan Endres
Journal:  J Natl Cancer Inst       Date:  2014-11-24       Impact factor: 13.506

6.  Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: ncic ctg ov.21.

Authors:  H J Mackay; D Provencheur; M Heywood; D Tu; E A Eisenhauer; A M Oza; R Meyer
Journal:  Curr Oncol       Date:  2011-04       Impact factor: 3.677

7.  Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

Authors:  Cor Hj Lamers; Stefan Sleijfer; Sabine van Steenbergen; Pascal van Elzakker; Brigitte van Krimpen; Corrien Groot; Arnold Vulto; Michael den Bakker; Egbert Oosterwijk; Reno Debets; Jan W Gratama
Journal:  Mol Ther       Date:  2013-02-19       Impact factor: 11.454

8.  A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.

Authors:  Mythili Koneru; Roisin O'Cearbhaill; Swati Pendharkar; David R Spriggs; Renier J Brentjens
Journal:  J Transl Med       Date:  2015-03-28       Impact factor: 5.531

9.  4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.

Authors:  Adrienne H Long; Waleed M Haso; Jack F Shern; Kelsey M Wanhainen; Meera Murgai; Maria Ingaramo; Jillian P Smith; Alec J Walker; M Eric Kohler; Vikas R Venkateshwara; Rosandra N Kaplan; George H Patterson; Terry J Fry; Rimas J Orentas; Crystal L Mackall
Journal:  Nat Med       Date:  2015-05-04       Impact factor: 53.440

10.  A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.

Authors:  Lana E Kandalaft; Daniel J Powell; George Coukos
Journal:  J Transl Med       Date:  2012-08-03       Impact factor: 5.531
View more
  6 in total

Review 1.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

2.  Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.

Authors:  Tong Li; Jiandong Wang
Journal:  BMC Cancer       Date:  2020-07-20       Impact factor: 4.430

Review 3.  Neuroblastoma Origin and Therapeutic Targets for Immunotherapy.

Authors:  Irina V Kholodenko; Daniel V Kalinovsky; Igor I Doronin; Sergey M Deyev; Roman V Kholodenko
Journal:  J Immunol Res       Date:  2018-07-11       Impact factor: 4.818

Review 4.  Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points.

Authors:  Janina Świderska; Mateusz Kozłowski; Sebastian Kwiatkowski; Aneta Cymbaluk-Płoska
Journal:  Cancers (Basel)       Date:  2021-12-01       Impact factor: 6.639

Review 5.  Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics.

Authors:  Curtis W McCloskey; Galaxia M Rodriguez; Kristianne J C Galpin; Barbara C Vanderhyden
Journal:  Cancers (Basel)       Date:  2018-07-26       Impact factor: 6.639

Review 6.  Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment.

Authors:  Katarzyna M Terlikowska; Bożena Dobrzycka; Sławomir J Terlikowski
Journal:  Int J Mol Sci       Date:  2021-03-28       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.